Application of electroretinography (ERG) in early drug development for assessing retinal toxicity in rats

Toxicol Appl Pharmacol. 2015 Dec 15;289(3):525-33. doi: 10.1016/j.taap.2015.10.008. Epub 2015 Oct 19.

Abstract

Retinal ocular toxicity is among the leading causes of drug development attrition in the pharmaceutical industry. Electroretinography (ERG) is a non-invasive functional assay used to assess neuro-retinal physiological integrity by measuring the electrical responses. To directly assess the utility of ERG, a series of studies was conducted following intravitreal and/or iv administration of pan-cyclin-dependent kinase inhibitors: AG-012,986 and AG-024,322 in rats. Both compounds have previously shown to induce retinal toxicity. Retinal injury was evaluated by ERG, histopathology and TUNEL staining. Intravitreal injection of AG-012,986 at ≥ 10 μg/eye resulted in decreases (60%) in ERG b-wave and microscopic changes of mild to moderate retinal degeneration, and at 30 μg/eye led to additional ophthalmic findings. Intravenous administration of AG-012,986 daily at ≥ 5 mg/kg resulted in dose-related decreases (25 to 40%) in b-wave and sporadic to intense positive TUNEL staining. Intravitreal injection of AG-024,322 at 30 μg/eye also resulted in decreases (50 to 60%) in b-wave, mild to marked retinal degeneration and mild vitreous debris. These experiments demonstrate that ERG can be used as a sensitive and reliable functional tool to evaluate retinal toxicity induced by test compounds in rats complementing other classical ocular safety measurements.

Keywords: Electroretinography; Pan-cyclin dependent kinase inhibitors; Rats; Retina; Toxicity.

MeSH terms

  • Animals
  • Benzamides / administration & dosage
  • Benzamides / adverse effects*
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / adverse effects*
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Cyclin-Dependent Kinases / metabolism
  • Drug Discovery / methods
  • Electroretinography / methods
  • In Situ Nick-End Labeling / methods
  • Indazoles / administration & dosage
  • Indazoles / adverse effects*
  • Intravitreal Injections / methods
  • Male
  • Rats
  • Retina / drug effects*
  • Retina / pathology*
  • Retinal Degeneration / pathology
  • Thiazoles / administration & dosage
  • Thiazoles / adverse effects*

Substances

  • AG-012986
  • Benzamides
  • Benzimidazoles
  • Indazoles
  • N-((5-(3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl)-4-methylpyridin-3-yl)methyl)ethanamine
  • Thiazoles
  • Cyclin-Dependent Kinases